In this long-term follow up of the ABSORB IV trial, the five-year rate of target lesion failure was significantly higher with the everolimus-eluting bioabsorbable scaffold compared with its metallic counterpart, despite strict adherence to recommended implantation techniques.
ABSTRACT & COMMENTARY
Absorb Stent Disappoints Again in 5-Year Data
July 1, 2023